These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 24863312)

  • 1. Comparative models of cervical cancer screening in Manitoba.
    DeRiviere L; Stopera S; Caeseele PV; Lotocki R
    Healthc Q; 2013; 16(1):77-85. PubMed ID: 24863312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
    Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
    Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of cytological test for cervices to identify human papillomavirus in the screening program on serious cervical lesion].
    Wang GP; Li RZ; Wu LN; Li J; Liu ZH; Wang C; Zhou YQ; Weng LM; Wu RF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):626-30. PubMed ID: 19957634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Holmes J; Hemmett L; Garfield S
    Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme.
    Confortini M; Giorgi Rossi P; Barbarino P; Passarelli AM; Orzella L; Tufi MC
    J Med Screen; 2010; 17(2):79-86. PubMed ID: 20660436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
    Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
    Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
    J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary human papillomavirus testing in organized cervical screening.
    Dillner J
    Curr Opin Obstet Gynecol; 2013 Feb; 25(1):11-6. PubMed ID: 23299089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.
    Nishino HT; Tambouret RH; Wilbur DC
    Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?
    Wright TC
    Clin Obstet Gynecol; 2007 Jun; 50(2):313-23. PubMed ID: 17513921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.
    Lazcano-Ponce E; Lorincz AT; Cruz-Valdez A; Salmerón J; Uribe P; Velasco-Mondragón E; Nevarez PH; Acosta RD; Hernández-Avila M
    Lancet; 2011 Nov; 378(9806):1868-73. PubMed ID: 22051739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm.
    Tota JE; Bentley J; Blake J; Coutlée F; Duggan MA; Ferenczy A; Franco EL; Fung-Kee-Fung M; Gotlieb W; Mayrand MH; McLachlin M; Murphy J; Ogilvie G; Ratnam S
    Prev Med; 2017 May; 98():5-14. PubMed ID: 28279264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study will assess whether HPV test should replace smears to screen for cervical cancer.
    Wise J
    BMJ; 2012 May; 344():e3744. PubMed ID: 22641810
    [No Abstract]   [Full Text] [Related]  

  • 15. Costs of integrating cervical cancer screening at an HIV clinic in Kenya.
    Vodicka EL; Babigumira JB; Mann MR; Kosgei RJ; Lee F; Mugo NR; Okech TC; Sakr SR; Garrison LP; Chung MH
    Int J Gynaecol Obstet; 2017 Feb; 136(2):220-228. PubMed ID: 28099724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening.
    Nghiem VT; Davies KR; Beck JR; Follen M; MacAulay C; Guillaud M; Cantor SB
    Br J Cancer; 2015 Jun; 112(12):1951-7. PubMed ID: 25919612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does cost-effectiveness analysis make a difference? Lessons from Pap smears. Symposium.
    Hagen MD; Garber AM; Goldie SJ; Lafata JE; Mandelblatt J; Meltzer D; Neumann P; Siegel JE; Sox HC; Tsevat J
    Med Decis Making; 2001; 21(4):307-23. PubMed ID: 11475387
    [No Abstract]   [Full Text] [Related]  

  • 18. The utility and cost-effectiveness of Pap test rescreening.
    Raab SS
    Clin Lab Manage Rev; 1998; 12(2):91-6. PubMed ID: 10178714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capsule Commentary on Jin et. al., Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women above Age 30 Years.
    Walsh J
    J Gen Intern Med; 2016 Nov; 31(11):1358. PubMed ID: 27384535
    [No Abstract]   [Full Text] [Related]  

  • 20. Performance of an Human Papillomavirus Test in Samples From Women With Histopathologically Confirmed Invasive Cervical Cancer.
    Denny L; Mbatani N; Adams T; Van Wijk L; Behrens C; Tam T; Wright T; Stoler M
    J Low Genit Tract Dis; 2016 Jul; 20(3):e52-3. PubMed ID: 27224533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.